Optinose announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. Prior to founding Fletcher Spaght, John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.185 USD | +4.87% | +13.94% | -8.14% |
May. 14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.14% | 164M | |
+31.37% | 588B | |
-2.60% | 364B | |
+20.83% | 326B | |
+5.69% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.77% | 167B | |
+0.10% | 161B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director